open access

Vol 4, No 2 (2019)
REVIEW ARTICLES
Published online: 2019-03-19
Get Citation

Limitations of molecularly targeted therapy

Karolina Balik, Paulina Modrakowska, Małgorzata Maj, Łukasz Kaźmierski, Anna Bajek
DOI: 10.5603/MRJ.a2019.0016
·
Medical Research Journal 2019;4(2):99-105.

open access

Vol 4, No 2 (2019)
REVIEW ARTICLES
Published online: 2019-03-19

Abstract

Personalized medicine is an extension of traditional medicine is based on a highly individual approach to each
patient. One of the most important tools that allow this approach is targeted therapy. It focuses mainly on
blocking cancer cell’s proliferation and angiogenesis capabilities by interfacing with specific molecules
that are involved in the growth and progression of the tumour. Small-molecule inhibitors and monoclonal
antibodies are the main drugs that are currently in use in order to affect the specific biochemical pathways
in cancer cells. However, likewise any other cancer therapies, targeted therapy has its own limitations. For
instance, identifying a molecular target needed to begin treatment is one of those hardships. A specific
molecule is crucial in this way of treatment. The other limitation is the toxicity that appears during the
treatment, the same as in the case of traditional chemotherapy and radiotherapy. Furthermore, the cost
of this therapy is significantly higher compared to classical treatments. However, the main obstacles are
mechanisms of cancer drug resistance which are often developing in response to given drugs. In many
cases, it makes further treatment impossible. This article is focusing on the limitations of molecularly
targeted therapy.

Abstract

Personalized medicine is an extension of traditional medicine is based on a highly individual approach to each
patient. One of the most important tools that allow this approach is targeted therapy. It focuses mainly on
blocking cancer cell’s proliferation and angiogenesis capabilities by interfacing with specific molecules
that are involved in the growth and progression of the tumour. Small-molecule inhibitors and monoclonal
antibodies are the main drugs that are currently in use in order to affect the specific biochemical pathways
in cancer cells. However, likewise any other cancer therapies, targeted therapy has its own limitations. For
instance, identifying a molecular target needed to begin treatment is one of those hardships. A specific
molecule is crucial in this way of treatment. The other limitation is the toxicity that appears during the
treatment, the same as in the case of traditional chemotherapy and radiotherapy. Furthermore, the cost
of this therapy is significantly higher compared to classical treatments. However, the main obstacles are
mechanisms of cancer drug resistance which are often developing in response to given drugs. In many
cases, it makes further treatment impossible. This article is focusing on the limitations of molecularly
targeted therapy.

Get Citation

Keywords

molecularly targeted therapy, anti-cancer drugs, cancer drug resistance, the toxicity of anti-cancer drugs

About this article
Title

Limitations of molecularly targeted therapy

Journal

Medical Research Journal

Issue

Vol 4, No 2 (2019)

Pages

99-105

Published online

2019-03-19

DOI

10.5603/MRJ.a2019.0016

Bibliographic record

Medical Research Journal 2019;4(2):99-105.

Keywords

molecularly targeted therapy
anti-cancer drugs
cancer drug resistance
the toxicity of anti-cancer drugs

Authors

Karolina Balik
Paulina Modrakowska
Małgorzata Maj
Łukasz Kaźmierski
Anna Bajek

References (41)
  1. Huang M, Shen A, Ding J, et al. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014; 35(1): 41–50.
  2. Krajewski KM, Braschi-Amirfarzan M, DiPiro PJ, et al. Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities. Korean J Radiol. 2017; 18(1): 28–41.
  3. Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol. 2012; 9(9): 542–548.
  4. Targeted Cancer Therapies. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet (22.01.2019).
  5. Zuazo-Gaztelu I, Casanovas O. Unraveling the Role of Angiogenesis in Cancer Ecosystems. Front Oncol. 2018; 8: 248.
  6. Ohhara Y, Fukuda N, Takeuchi S, et al. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol. 2016; 8(9): 642–655.
  7. Jackisch C, Lammers P, Jacobs I. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars. Breast. 2017; 32: 199–216.
  8. Vennepureddy A, Thumallapally N, Motilal Nehru V, et al. Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. J Clin Med Res. 2016; 8(2): 63–75.
  9. NCI Drug Dictionary. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-drug (23.01.2019).
  10. Powroźnik B, Kubowicz P, Pękala E. Monoclonal antibodies in targeted therapy. Postepy Hig Med Dosw (Online). 2012; 66: 663–673.
  11. Lupu I, Voiculescu N, Bacalbasa N, et al. Cutaneous complications of molecular targeted therapy used in oncology. J Med Life. 2016; 9(1): 19–25.
  12. Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol. 2015; 2(4): e1004969.
  13. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007; 25(34): 5390–5396.
  14. Liu Hb, Wu Y, Lv Tf, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013; 8(1): e55128.
  15. Rinderknecht JD, Goldinger SM, Rozati S, et al. RASopathic skin eruptions during vemurafenib therapy. PLoS One. 2013; 8(3): e58721.
  16. Adjuvant Breast Cancer Treatment Side Effects. Herceptin (trastuzumab). http://www.herceptin.com/hcp/treatment/adjuvant/side-effects, (24.01.2019.).
  17. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3): 719–726.
  18. Tang N, Ratner D. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer. Dermatol Surg. 2016; 42 Suppl 1: S40–S48.
  19. de Golian E, Kwong BY, Swetter SM, et al. Cutaneous Complications of Targeted Melanoma Therapy. Curr Treat Options Oncol. 2016; 17(11): 57.
  20. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015; 7(2): 122–136.
  21. Sondermann W, Griewank KG, Schilling B, et al. Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection. PLoS One. 2015; 10(4): e0124590.
  22. Shu M, Zai X, Zhang B, et al. Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses. PLoS One. 2016; 11(1): e0147048.
  23. Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci. 2010; 101(4): 963–968.
  24. Daimon M, Kato T, Kaino W, et al. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012; 42(8): 742–747.
  25. Faruque LI, Lin M, Battistella M, et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS One. 2014; 9(7): e101145.
  26. Sasich LD, Sukkari SR. The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). Saudi Pharm J. 2012; 20(4): 381–385.
  27. Feliu J, Salud A, Safont MJ, et al. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One. 2015; 10(1): e0116527.
  28. Zuo PY, Chen XL, Liu YW, et al. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS One. 2014; 9(7): e102484.
  29. Guan M, Zhou YP, Sun JL, et al. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int. 2015; 2015: 428169.
  30. Styczyński J, Haus O. [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults]. Postepy Hig Med Dosw (Online). 2006; 60: 527–537.
  31. Asić K. Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies. Crit Rev Oncol Hematol. 2016; 97: 178–196.
  32. Spaans JN, Goss GD. Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. Front Oncol. 2014; 4: 190.
  33. Fiszman GL, Jasnis MA. Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. Int J Breast Cancer. 2011; 2011: 352182.
  34. Wragg JW, Heath VL, Bicknell R. Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors. Cancer Res. 2017; 77(4): 1008–1020.
  35. Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014; 13(12): 928–942.
  36. Jakka S, Rossbach M. An economic perspective on personalized medicine. The HUGO Journal. 2013; 7(1): 1.
  37. Elkin EB, Marshall DA, Kulin NA, et al. Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med. 2011; 13(10): 853–860.
  38. Raab SS. The cost-effectiveness of immunohistochemistry. Arch Pathol Lab Med. 2000; 124(8): 1185–1191, doi: 10.1043/0003-9985(2000)124<1185:TCEOI>2.0.CO;2.
  39. Leung W, Kvizhinadze G, Nair N, et al. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis. PLoS Med. 2016; 13(8): e1002067.
  40. Jackson DB, Sood AK. Personalized cancer medicine--advances and socio-economic challenges. Nat Rev Clin Oncol. 2011; 8(12): 735–741.
  41. Curl P, Vujic I, van 't Veer LJ, et al. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One. 2014; 9(9): e107255.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.